Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9862047 | 0.78 | MAOA (0.39) | MAOAMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9567365 | 0.71 | MAOB (0.39) | MAOAMAOBTSHRCYP1A2NPC1 | |
| SCHEMBL4486486 | 0.71 | TSHR (0.42) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL29471383 | 0.71 | — | — | |
| SCHEMBL59871 | 0.71 | — | — | |
| SCHEMBL30473446 | 0.71 | TSHR (0.42) | MAOAMAOBTSHRCA1CA2 | |
| Ammonia Solution, Strong SCHEMBL23320033 | 0.69 | MAOA (0.40) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL16439994 | 0.69 | — | — | |
| SCHEMBL19308401 | 0.67 | MAOA (0.39) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL8535446 | 0.67 | MAOA (0.39) | MAOAMAOBTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511473-B1 | BIS-AROMATIC ALKANOLS | NOVARTIS AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-1594508-B1 | NOVEL BICYCLIC COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2012-08-08 | — | — | EP | disclosed |
| EP-1622866-B1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| EP-1636171-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-1622860-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs | NOVARTIS AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2011-05-19 | — | — | US | disclosed |
| US-7902175-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-7825260-B2 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7696184-B2 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20060264403-A1 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2006-11-23 | — | — | US | disclosed |
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| US-20060166940-A1 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1377593-B1 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1594508-A2 | NOVEL BICYCLIC COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-11-16 | — | — | EP | disclosed |
| US-20040248952-A1 | Novel bicyclic compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004071442-A2 | NOVEL BICYCLIC COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-08-26 | — | — | WO | disclosed |
| US-20040147490-A1 | 2-Amino-propanol derivatives | ALBERT RAINER (CH) | 2004-07-29 | — | — | US | disclosed |
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | IRM LLC (BM) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | S1PR1, S1PR3, S1PR2 | MAOA 3813/4885MAOB 2966/4885TSHR 310/4885 |
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | MAOA 1936/4885MAOB 1679/4885TSHR 2857/4885 |
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | CD4, HLA-DRB1, MALT1 | MAOA 1165/4885MAOB 717/4885TSHR 1306/4885 |
| US-20040248952-A1 | Novel bicyclic compounds and compositions | S1PR1, S1PR3, S1PR5 | MAOA 4038/4885MAOB 3848/4885TSHR 2217/4885 |
| US-20060166940-A1 | Amino-propanol derivatives | ADRB1, ADRB3, ADRA1D | MAOA 3877/4885MAOB 3733/4885TSHR 902/4885 |
| US-20040147490-A1 | 2-Amino-propanol derivatives | CD4, HLA-DRB1, CCR1 | MAOA 3700/4885MAOB 3513/4885TSHR 1586/4885 |
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | MAOA 1936/4885MAOB 1679/4885TSHR 2857/4885 |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | S1PR1, S1PR3, S1PR2 | MAOA 4186/4885MAOB 3637/4885TSHR 290/4885 |
| US-20060264403-A1 | Aminopropanol derivatives | ADRB1, ADRA1D, ADRA1A | MAOA 1936/4885MAOB 1679/4885TSHR 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.